Merck Enlicitide Lowers LDL vs Non-Statins Merck's enlicitide showed ~38% LDL reduction vs ~11% for non-statins (Mar 30, 2026 report); the oral PCSK9 candidate could broaden treatment but faces regulatory and payer hurdles.

Merck Enlicitide Lowers LDL vs Non-Statins: Merck's enlicitide showed ~38% LDL reduction vs ~11% for non-statins (Mar 30, 2026 report); the oral PCSK9 candidate could broaden treatment but faces regulatory and payer hurdles. 👈 Read full analysis #Merck #Enlicitide #LDL #PCSK9 #Cholesterol

The #PCSK9 inhibitor evolocumab ↘️ the risk of a first major CV event in patients w/ diabetes without known significant atherosclerosis, according to a prespecified subgroup analysis of the VESALIUS-CV trial, presented during a LBCT session at #ACC26. 🔗 https://bit.ly/3PBZqLo

JAMA Cardiology editorial titled "The Cost-Effectiveness Evolution of Cardiovascular Care" by Gregg C. Fonarow text@1, Ann Marie Navar text@2, Clyde W. Yancy text@3. Published Online: February 4, 2026. doi: 10.1001/jamacardio.2025.5240.

💬 Editorial: Price reductions for #PCSK9 inhibitors and #Semaglutide substantially improved cost-effectiveness and access, highlighting the need for value-based drug pricing in cardiovascular care.

ja.ma/4l4cOn5

How can LDL-cholesterol ("bad" cholesterol) be lowered in patients? Danila Branca gave an exciting talk at #Lunteren2026 on the development of orally bioavailable, macrocyclic peptide-based inhibitors of PCSK9.

pubs.acs.org/doi/10.1021/...
#DrugDiscovery #Peptide #Macrocycle #Cholesterol #PCSK9

In a phase 1 trial with 6 patients, #lipid nanoparticles for #PCSK9 base editing lowered #LDL without serious adverse events or off-target effects. https://www.nature.com/articles/s41591-026-04254-4

New complimentary #CME!
Get a quick, practical update on LDL-C management in high-risk #ASCVD, including clinical data on new and emerging PCSK9 inhibitors (injectable & oral).

Earn 0.5 CME in 30 minutes.
clinical.med-iq.com/activity/ldl...

#CardioTwitter #MedEd #PCSK9

New in Healthcare and Rehabilitation:
MR analysis found no causal link between HMGCR or NPC1L1 inhibition and low back pain; PCSK9 showed weak, borderline evidence of a protective association.
doi.org/10.1016/j.hc...
#LowBackPain #PCSK9 #MendelianRandomization

An editorial from JAMA Cardiology titled "The Cost-Effectiveness Evolution of Cardiovascular Care" by Gregg C. Fonarow et al. It discusses proprotein convertase subtilisin/kexin type 9 inhibitors(PCSK9i) and the glucagon-like peptide-1 receptor agonist (GLP-1RA).

💬 Editorial: Price reductions for #PCSK9 inhibitors and #Semaglutide substantially improved cost-effectiveness and access, highlighting the need for value-based drug pricing in cardiovascular care.

ja.ma/4rpH3XC

Cadmium Exposure is Associated with the Prevalence of Dyslipidemia Abstract. Background: Cadmium is a widespread environmental and occupational pollutant that accumulates in human body with a biological half-life exceeding 10 years. Cadmium exposure has been demonstr...

#PCSK9 #agedcare #ecology #health #sustainability

Exposure to toxic metals
needs to be monitored and addressed.

The prevalence of

high total cholesterol,
high triglycerides,
and high LDL-C,

increased dose-dependently
with increases in
blood cadmium (Cd).
.
karger.com/cpb/article/...

Oral PCSK9 Therapy And The Future Of Heart Disease - Dr. Christie Ballantyne MD, Baylor College of Medicine & Dr. Alexander Tal, MD join me on Progress, Potential, And Possibilities #Cardiology #Atherosclerosis #HeartDiseasePrevention #Enlicitide #PCSK9 - www.youtube.com/watch?v=ANPe...

💊FDA Approval Update | #Lerochol (#Lerodalcibep-liga)
🔸A third-generation #PCSK9 inhibitor that can reduce #LDL-C in #hypercholesterolemia
🌟Achieved approximately 50% reduction in apolipoprotein B levels + a 24% reduction in lipoprotein(a) in Phase III trial

Expanded Indication for PCSK9 Inhibitors
Free access: medicalletter.org/pcsk744a

#PCSK9 #CardiovascularRisk #FOAMed

Read our latest issue: bit.ly/4rQjrwc

#PCSK9 #Menopause #Migraine

Computer-aided design enables repurposing of proprotein convertase subtilisin/kexin type 9 degrader from cholesterol-lowering to colon cancer therapy - Molecular Biomedicine Molecular Biomedicine -

#Letter
omputer-aided design enables #repurposing of proprotein convertase subtilisin/kexin type 9 degrader from #cholesterol-lowering to colon #cancer therapy doi.org/10.1186/s435...

#ColorectalCancer #CRC #PCSK9 #LDL #LDLR #EMT

🧪Is there still space today to conduct #drugdiscovery without relying on AI-driven tools?
We describe the integration of functional assays, #greenchemistry and late-stage functionalization to develop metabolically stable #PCSK9 modulators.
chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...

AHA: MSD's oral PCSK9 matches injectables MSD closes on filing for enlicitide, a PCSK9 inhibitor that could offer the efficacy of injectables with the ease of a once-daily pill

MSD closes on filing for enlicitide, a #PCSK9 inhibitor that could offer the efficacy of injectables with the ease of a once-daily pill. #CardiovascularHealth
pharmaphorum.com/news/aha-msd...

[#MedizinischeStudien #PCSK9] Überblick: VESALIUS-CV war eine randomisierte, doppelblinde Studie mit über 12.000 Hochrisikopatienten (ASCVD/Diabetes) ohne Vorerankung. Die Sicherheit war konsistent, keine neuen Signale. #Cholesterin #Gesundheit

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, s...

Impressive risk reduction on top of statins #CVD #Heartdisease #PCSK9 www.nejm.org/doi/full/10....

Remarkable, groundbreaking progress for cardiometabolic science and medicine!!! #FGF21R #GLP1 #APOC3 #ANGPTL3 #PCSK9 #mAb #siRNA #ASO #CRISPRCas9
Shoutout to ♥️ basic and clinical scientists moving this forward for our patients! @ahascience.bsky.social #AHA25 #PrevCards #Lipidology

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions Summary of PCSK9 inhibitor mechanisms. PCSK9 inhibitors (PCSK9-i) primarily lower LDL-cholesterol (LDL-C) by blocking PCSK9-mediated degradation of hepatic LDL receptors (LDLR), enhancing LDL clearan....

#Review in #MedComm
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions doi.org/10.1002/mco2...

#PCSK9 #LDL_C #IschemicStroke #Intervention #Strategies #PrecisionTherapy #therapeutics

Dr. Augusto Bleve representing #Italian #Network for #Tumor #Biotherapy ( #NIBIT ) talks on role of #hypercholesterolemia on #anticancer #immunity / #PCSK9 #RORgamma #WIC2025 #SITC2025

📣 PCSK9 for prediction of adverse limb outcomes after endovascular #revascularization in diabetic chronic limb-threatening ischemia

📌 Biscetti et al. show that higher #PCSK9 levels linked to increased major adverse limb events among diabetic patients

🆓 on TH: www.thieme-connect.de/products/ejo...

Non-hepatic #PCSK9

PCSK9 overexpression regulates #ExtracellularVescle cargo packaging (Proteome microRNA array) in #SmoothMuscleCell▶️
👉⏫Inflammation in #EndothelialCell Mφ
👉⏫Migration ⏫oxLDL uptake ⏬OXPHOS ⏫Glycolysis in Mφ
👉Recruit more Mφ in🐟brain/muscle

#IJMS 2025
www.mdpi.com/1422-0067/23...

Non-hepatic #PCSK9

PCSK9 targets LRP2/Megalin to lysosomal degradation in renal proximal tubule cells

Megalin mediates PCSK9 uptake in renal epithelium

PCSK9 KO🐭 or Alirocumab in WT or nephrotic Nphs2-/-🐭
⏫renal Megalin & LDLR
⏬ #Proteinuria

#KidneyInt 2023
www.sciencedirect.com/science/arti...

‘This is revolutionary!’: Breakthrough cholesterol treatment can cut levels by 69% after one dose | BBC Science Focus Magazine The future of heart attack prevention could be as easy as a single injection

New one and done #VERVE102 gene altering shot permanently lowers LDL cholesterol by turning off your #PCSK9 gene. Goal is to reduce your chance of a heart attack. #BraveNewWorld

www.sciencefocus.com/news/new-cho...

Hypercholestérolémie familiale : la santé de patients au cœur d’un bras de fer économique Des milliers de Français, atteints d’hypercholestérolémie grave, sont démunis face à la pénurie et à la menace de déremboursement de traitements vitaux. Un différend entre Sanofi et les autorités de s...

sante.lefigaro.fr/medecine/hyp...

Hypercholestérolémie familiale : des patients privés de traitement vital, un labo qui menace de sortir du remboursement, une HAS inflexible sur ses critères.
Innovation vs évaluation : le bras de fer se joue… sur le dos des malades.
#santé #cholestérol #PCSK9

🧬 New in AJPC: Real-world data from a preventive cardiology clinic reveals sex differences in treatment with PCSK9 monoclonal antibodies.

Explore the findings 👉 ow.ly/PnwH50Wf9C7

#PreventiveCardiology #PCSK9 #Cholesterol #SexDifferences #AJPC #CardiologyResearch #cardiosky #medsky

Cardiovascular Weekly News – June 12th 2025 🫀 Cardiovascular Update: CABG Boosts Survival, Polymer Valve Approved, PCSK9 Pill Succeeds and More   From revolutionary valves to powerful […] The post Cardiovascular Weekly News – June 12th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Cardiovascular Weekly News – June 12th 2025 #News #AFib #PCSK9 #ValveTherapy #EMSDisparities Comment below!

#PCSK9 #AbdominalAorticAneurysm

Global PCSK9 KO does Not modify serum lipids in ApoE SA/SA🐭+#WesternDiet!😨
But
⏫survival
⏬AAA
↔️aortic #SmoothMuscleCell content
⏬Mφ infiltr & inflammatory cytokines & MMP9

#ATVB 2025 @ahajournals.bsky.social
www.ahajournals.org/doi/10.1161/...

Cardiovascular Weekly News – June 12th 2025 🫀 Cardiovascular Update: CABG Boosts Survival, Polymer Valve Approved, PCSK9 Pill Succeeds and More   From revolutionary valves to powerful […] The post Cardiovascular Weekly News – June 12th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Cardiovascular Weekly News – June 12th 2025 #News #AFib #PCSK9 #ValveTherapy #EMSDisparities Comment below!